These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35963564)

  • 1. Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer.
    Yin X; Liao H; Yun H; Lin N; Li S; Xiang Y; Ma X
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):146-159. PubMed ID: 35963564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.
    Yang Y; Liu H; Chen Y; Xiao N; Zheng Z; Liu H; Wan J
    Cell Death Dis; 2023 Mar; 14(3):230. PubMed ID: 37002211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.
    Mei T; Wang T; Zhou Q
    Clin Exp Med; 2024 Mar; 24(1):60. PubMed ID: 38554212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The artificial intelligence and machine learning in lung cancer immunotherapy.
    Gao Q; Yang L; Lu M; Jin R; Ye H; Ma T
    J Hematol Oncol; 2023 May; 16(1):55. PubMed ID: 37226190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
    Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
    Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Artificial Intelligence in Precise Assessment of Programmed Cell Death-ligand 1 and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
    Wu J; Lin D
    Adv Anat Pathol; 2021 Nov; 28(6):439-445. PubMed ID: 34623343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer.
    Cheng G; Zhang F; Xing Y; Hu X; Zhang H; Chen S; Li M; Peng C; Ding G; Zhang D; Chen P; Xia Q; Wu M
    Front Immunol; 2022; 13():893198. PubMed ID: 35844508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
    Cui R; Yang Z; Liu L
    Thorac Cancer; 2022 Oct; 13(19):2669-2680. PubMed ID: 36039482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When artificial intelligence meets PD-1/PD-L1 inhibitors: Population screening, response prediction and efficacy evaluation.
    Jin W; Luo Q
    Comput Biol Med; 2022 Jun; 145():105499. PubMed ID: 35439641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The EU-funded I
    Prelaj A; Ganzinelli M; Trovo' F; Roisman LC; Pedrocchi ALG; Kosta S; Restelli M; Ambrosini E; Broggini M; Pravettoni G; Monzani D; Nuara A; Amat R; Spathas N; Willis M; Pearson A; Dolezal J; Mazzeo L; Sangaletti S; Correa AM; Aguaron A; Watermann I; Popa C; Raimondi G; Triulzi T; Steurer S; Lo Russo G; Linardou H; Peled N; Felip E; Reck M; Garassino MC
    Clin Lung Cancer; 2023 Jun; 24(4):381-387. PubMed ID: 36959048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
    Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
    Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.